
QIAGEN N.V. QGEN
Annual report 2025
added 04-18-2026
QIAGEN N.V. Cost of Revenue 2011-2026 | QGEN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 801 M | 638 M | 521 M | 501 M | 495 M | 493 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 801 M | 493 M | 575 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
222 K | $ 1.29 | -20.86 % | $ 1.72 M | ||
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
176 M | $ 15.71 | -2.96 % | $ 475 M | ||
|
Agilent Technologies
A
|
2.91 B | $ 111.77 | -1.3 % | $ 34 B | ||
|
Castle Biosciences
CSTL
|
71 M | $ 19.2 | 1.69 % | $ 557 M | ||
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
1.51 B | $ 143.1 | -0.1 % | $ 22.8 B | ||
|
Interpace Biosciences
IDXG
|
14.6 M | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
45.5 M | $ 20.02 | -2.29 % | $ 1.07 B | ||
|
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | ||
|
Lantheus Holdings
LNTH
|
600 M | $ 94.21 | -2.55 % | $ 6.36 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | ||
|
Myriad Genetics
MYGN
|
248 M | $ 3.59 | -0.97 % | $ 332 M | ||
|
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
413 M | $ 8.26 | -1.2 % | $ 1.06 B | ||
|
Natera
NTRA
|
158 M | $ 188.46 | -4.22 % | $ 18.5 B | ||
|
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 25.24 | -1.02 % | $ 23.9 B | ||
|
Guardant Health
GH
|
349 M | $ 95.46 | -3.24 % | $ 12 B | ||
|
Senseonics Holdings
SENS
|
19.5 M | $ 5.76 | -1.12 % | $ 240 M | ||
|
Personalis
PSNL
|
53.9 M | $ 6.4 | -4.69 % | $ 571 M | ||
|
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
3.97 B | $ 115.74 | -1.15 % | $ 9.55 B | ||
|
Soleno Therapeutics
SLNO
|
2.7 M | $ 53.0 | 0.01 % | $ 2.69 B | ||
|
Biomerica
BMRA
|
4.81 M | $ 2.3 | -4.56 % | $ 5.28 M | ||
|
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 251.69 | -0.92 % | $ 20.9 B | ||
|
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.56 | -3.63 % | $ 201 M | ||
|
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
186 M | $ 49.03 | -7.4 % | $ 2.93 B | ||
|
Neogen Corporation
NEOG
|
473 M | $ 8.18 | -3.02 % | $ 1.77 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 187.21 | -0.39 % | $ 20.8 B | ||
|
Waters Corporation
WAT
|
363 M | $ 331.36 | -0.56 % | $ 19.7 B |